| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Liaoning He Eye Hospital Group Co., LTD. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥21.06 |
| 52 Week High | CN¥43.37 |
| 52 Week Low | CN¥19.97 |
| Beta | 0.72 |
| 11 Month Change | -13.37% |
| 3 Month Change | -26.11% |
| 1 Year Change | -48.38% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -50.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| 301103 | CN Healthcare | CN Market | |
|---|---|---|---|
| 7D | -6.3% | -6.4% | -4.7% |
| 1Y | -48.4% | -36.0% | -17.5% |
Return vs Industry: 301103 underperformed the CN Healthcare industry which returned -36% over the past year.
Return vs Market: 301103 underperformed the CN Market which returned -17.5% over the past year.
Price Volatility
| 301103 volatility | |
|---|---|
| 301103 Average Weekly Movement | 5.2% |
| Healthcare Industry Average Movement | 5.2% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in CN Market | 10.2% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 301103's share price has been volatile over the past 3 months.
Volatility Over Time: 301103's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 3,455 | Wei He | www.hsyk.com.cn |
Liaoning He Eye Hospital Group Co., LTD. provides eye medical service and optometry services. It offers ophthalmopathy in children and elderly, refraction, and ocular surface services.
Liaoning He Eye Hospital Group Co., LTD. Fundamentals Summary
| 301103 fundamental statistics | |
|---|---|
| Market cap | CN¥3.30b |
| Earnings (TTM) | CN¥35.70m |
| Revenue (TTM) | CN¥1.16b |
92.4x
P/E Ratio2.8x
P/S RatioIs 301103 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 301103 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.16b |
| Cost of Revenue | CN¥689.71m |
| Gross Profit | CN¥473.51m |
| Other Expenses | CN¥437.81m |
| Earnings | CN¥35.70m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.23 |
| Gross Margin | 40.71% |
| Net Profit Margin | 3.07% |
| Debt/Equity Ratio | 0% |
How did 301103 perform over the long term?
See historical performance and comparison